Oat Flakes β-glucan on Glycemic Variability, Pancreatic Reserve, and Dyslipidemia Among Adolescents With Type 1 Diabetes

NCT07593105 · Completed

Last updated 2026-05-28

This clinical trial tests whether eating oat flakes containing beta-glucan can help manage blood sugar levels in teenagers with type 1 diabetes.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) supportive care study

Participants 60 people

Who can join Ages 12–18 · all sexes

Timeline Started 2024-10 · est. completion 2026-02

Where 1 site · Egypt

What this study is testing ClinicalTrials.gov NCT07593105 ↗

Description as written by the study sponsor.

Chronic iron overload represents a significant morbidity in Transfusion dependent β-thalassemia (TDT) leading to various endocrine complications including diabetes. The GLP-1 receptor agonist (GLP-1RA) Dulaglutide has recently been approved for pediatric type 2 diabetes (T2D) treatment. Objectives: to assess the effect of Dulaglutide versus conventional insulin therapy on glycemic metrics, pancreatic reserve, dyslipidemia and ferritin among children and adolescents with TDT related diabetes.

Treatments tested

Oat Flour Dietary supplement

B-glucan oat flakes

Main thing measured	Glycemic control
Sponsor	Ain Shams University
Conditions studied	Type 1 Diabetes, Nutrition
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07593105 ↗